Aminoglycosides Market Size & Trends
The size of the global aminoglycosides market was estimated at USD 1.91 billion in 2024 and is expected to grow at a CAGR of 4.34% during the period from 2025 to 2030, due to the increasing rate of bacterial infections caused by gram-positive and gram-negative bacteria. As per a report released in April 2024, infections represented about 28% of the total disease burden, in 2019, among which bacterial infections were responsible for 14%, highlighting their far-reaching implications for global health. Severe bacterial infections are related to high levels of sickness and mortality; hence, the choice of proper therapy can have an important bearing on clinical outcomes.
Based on February 2025 CDC data, antimicrobial resistance (AMR) is considered a pressing public health threat internationally. In the United States, there are over 2.8 million annual infections that are resistant to antimicrobial agents, resulting in greater than 35,000 fatalities. Globally, AMR was directly responsible for at least 1.27 million deaths and accounted for close to 5 million deaths in 2019. Bacterial infections becoming more prevalent, antimicrobial resistance, and the dynamic use of aminoglycoside medicines to treat diseases are the major drivers of market growth for aminoglycosides. This drug class application in treatment is a major driver of growth.
In addition, the increasing number of tuberculosis cases is likely to drive aminoglycoside demand, particularly in low-income nations where the rate is high and requires TB drug regimens. In a CDC report of March 2025, 10,347 cases of tuberculosis (TB) were reported provisionally, resulting in a rate of 3.0 cases per 100,000 population in 2024. This is an increase of 8% in case numbers and a 6% increase in rates over 2023.
The World Health Organization (WHO) and the European Respiratory Society (ERS) have launched digital health programs for the elimination of tuberculosis (TB). These efforts are likely to improve TB prevention and treatment through the deployment of digital technologies.
In March 2024, the Johns Hopkins University Center for Global Digital Health Innovation published a research summary entitled “Digital Tools for Tuberculosis Management.” It was noted by WHO that there was a surge in growth in the TB drug pipeline of drug developments from 28 in 2023, and as of August 2024, 29 drugs were in clinical trials. This rapid growth mirrors TB drug development, which is fueled by higher investments from different funders and collaborative initiatives from various platforms. It also signaled that more efficient and varied therapeutic alternatives can soon improve TB care and management.
Pipeline Analysis
In a June 2023 article, Apramycin (EBL-1003), an aminoglycoside antibiotic developed by Juvabis AG, represents a milestone in the development of the market for aminoglycosides. Historically applied solely in veterinary medicine in the European Union, Apramycin has now entered clinical focus for human application after a Phase I clinical trial was successfully completed in October 2020. This marks a significant long-term market implication. With resistance to traditional antibiotics increasing, Apramycin’s proven effectiveness against multidrug-resistant Gram-negative pathogens makes it an attractive candidate for next-generation treatments.
Market Concentration & Characteristics
The level of innovation is high in the market with an increasing level of research and development. For instance, as per an article in 2022, scientists have investigated the application of gold nanoparticles conjugated with aminoglycosides such as ribostamycin. This synergy increases antibacterial activity, providing a promising solution to fight resistant bacterial strains. Moreover, research on aminoglycosides is being undertaken to minimize toxicity, enhance drug availability, and decrease doses. Aminoglycoside antibiotics are being integrated into different nanoparticle carriers as a new approach to increase their antibacterial activity and minimize systemic toxicity.
Product Insights
Product-wise, the market has been divided into Neomycin, streptomycin, gentamicin, kanamycin, tobramycin, amikacin, and others included in the product classification of aminoglycosides. Gentamicin dominated the market and represented 34.24% of the revenue worldwide in 2024. Developments in gentamicin have taken a great leap, ushering in new options marked by increased efficacy, delivery forms, and tolerability. An example is the Food and Drug Administration (FDA) approval of Cerament G, a resorbable, gentamicin-eluting ceramic bone void filler, for skeletally mature patients in May 2022.
Route of Administration Insights
On the basis of route of administration, the market is divided into injectable, feed, intra-mammary, topical, oral, and injectable, which dominated the market with a market share of 26.73% in 2024. Injectable medicines tend to deliver quick and effective relief from infection and hence are the first choice for people suffering from severe or acute infections.
In February 2024,Cipla extended its dedication to the fight against antimicrobial resistance (AMR) by obtaining approval from India’s Central Drugs Standard Control Organization (CDSCO) to launch ZEMDRI (plazomicin) injection in the Indian market. Plazomicin is a new intravenous (IV) aminoglycoside antibiotic used to treat complicated urinary tract infections (cUTI), including pyelonephritis. Insmed Incorporated reported on September 2023 positive topline results from the Phase 3 study of ARIKAYCE (amikacin liposome inhalation suspension) in patients with newly diagnosed or recurrent non-tuberculous mycobacterial (NTM) lung disease.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Route of Administration
1.2.3. Application
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product and route of administration outlook
2.2.2. Application outlook
2.2.3. Regional outlook
2.3. Competitive Insights
